Company intelligence / Profile preview
Eno Pharmaceutical
Beijing, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Eno Pharmaceutical is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal disorders. The company's lead candidate is a potassium-competitive acid blocker (P-CAB) designed to provide faster and more sustained acid suppression compared to traditional proton pump inhibitors. Eno Pharmaceutical is currently advancing its primary asset through late-stage clinical trials for indications such as erosive esophagitis and peptic ulcers. The company aims to address unmet medical needs in the acid-related disease market by offering improved safety and efficacy profiles.
- Therapeutic areas
- Gastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Eno Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eno Pharmaceutical.